Lymphocytic Redemption: Letermovir Conversion for Primary CMV Prophylaxis in Thoracic versus Abdominal Transplant (WTC 2025) - Jul 30, 2025 - Abstract #P2.05.16; Pres time: Aug 4, 2025; 03:30 PM - 04:30 PM; Location: Exhibit Hall AB; "Patients were excluded for ganciclovir/valganciclovir use for 7 days. We observed no difference in rates of WBC improvement for CT vs. AT recipients at 30 days following conversion to LTV."
Cytomegalovirus Infection • Infectious Disease • Transplantation
|
|
S. Amin; A. Yun; M. Nigo; A. Hutchins; A. Scott; A. Chaplain; E. Rubido; T. Pasley; A. Rogers
|